SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lamm DL. Carcinoma in situ. Urol Clin North Am 1992; 19: 499508
  • 2
    Wolf H, Melsen F, Pedersen SE, Nielsen KT. Natural history of carcinoma in situ of the urinary bladder. Scand J Urol Nephrol Suppl 1994; 157: 14751
  • 3
    Sylvester RJ, van der Meijden A, Witjes JA et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 2005; 66: 90107
  • 4
    Lamm DL, Herr H, Jakse G et al. Updated concepts and treatment of carcinoma in situ. Urol Oncol 1998; 4: 1308
  • 5
    Griffiths TR, Charlton M, Neal DE, Powell PH. Treatment of carcinoma in situ with intravesical bacillus Calmette–Guérin without maintenance. J Urol 2002; 167: 240812
  • 6
    Witjes JA. Bladder carcinoma in situ in 2003: state of the art. Eur Urol 2004; 45: 1426
  • 7
    Ovesen H, Horn T, Steven K. Long-term efficacy of intravesical bacillus Calmette–Guérin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation. J Urol 1997; 157: 16559
  • 8
    Jakse G, Hall R, Bono A et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. Eur Urol 2001; 40: 14450
  • 9
    Losa A, Hurle R, Lembo A. Low dose bacillus Calmette–Guérin for carcinoma in situ of the bladder: long-term results. J Urol 2000; 163: 6871; discussion 72
  • 10
    de Reijke TM, Kurth KH, Sylvester RJ et al. Bacillus Calmette–Guérin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer – Genito-Urinary Group Phase III Trial (30906). J Urol 2005; 173: 4059
  • 11
    Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette–Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163: 11249
  • 12
    De Jager R, Guinan P, Lamm D et al. Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette–Guérin. Overview analysis of six phase II clinical trials. Urology 1991; 38: 50713
  • 13
    Hudson MA, Herr HW. Carcinoma in situ of the bladder. J Urol 1995; 153: 56472
  • 14
    Solsona E, Iborra I, Ricos JV, Dumont R, Casanova JL, Calabuig C. Upper urinary tract involvement in patients with bladder carcinoma in situ (Tis): its impact on management. Urology 1997; 49: 34752
  • 15
    Comprehensive Cancer Centers. Available at: http://www.cancerregistry.nl. Accesses 18 May 2009
  • 16
    Fritz A, Percy C, Jack A et al. eds. International Classification of Diseases for Oncology. Geneva: WHO, 2000
  • 17
    Sobin DHW, Wittekind Ch eds. TNM Classification of Malignant Tumours, 6th edn. Wilmington, DE: Wiley-Liss, 2002
  • 18
    Visser O, Siesling S, van Dijck J. Incidence of Cancer in the Netherlands 1999/2000. Utrecht: Vereniging van Integrale Kankercentra, 2003
  • 19
    Schouten LJ, Hoppener P, van den Brandt PA, Knottnerus JA, Jager JJ. Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol 1993; 22: 36976
  • 20
    Lamm DL, Blumenstein BA, Crawford ED et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette–Guérin for transitional-cell carcinoma of the bladder. N Engl J Med 1991; 325: 12059
  • 21
    Lundholm C, Norlen BJ, Ekman P et al. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette–Guérin in patients with superficial bladder carcinoma. J Urol 1996; 156: 3726
  • 22
    Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette–Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 196470
  • 23
    Kaasinen E, Wijkstrom H, Malmstrom PU et al. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. Eur Urol 2003; 43: 63745
  • 24
    van Gils-Gielen RJ, Witjes WP, Caris CT, Debruyne FM, Witjes JA, Oosterhof GO. Risk factors in carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Urology 1995; 45: 5816
  • 25
    Malkowicz SB, Nichols P, Lieskovsky G, Boyd SD, Huffman J, Skinner DG. The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2). J Urol 1990; 144: 6415
  • 26
    Tsujihashi H, Nakanishi A, Matsuda H, Uejima S, Akiyama T, Kurita T. Clinical assessment of carcinoma in situ of the human urinary bladder. Int Urol Nephrol 1992; 24: 24354
  • 27
    Shariat SF, Kim J, Raptidis G, Ayala GE, Lerner SP. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 2003; 61: 11405